[{"id":"f8a952e4-5c1e-4c1d-b24f-75b41328f45f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05089266","created_at":"2021-10-22T12:53:00.028Z","updated_at":"2024-07-02T16:35:42.867Z","phase":"Phase 1","brief_title":"Study of αPD1-MSLN-CAR T Cells to Evaluate the Safety, Tolerability, and Effectiveness for Patients With MSLN-positive Advanced Solid Tumors","source_id_and_acronym":"NCT05089266","lead_sponsor":"Shanghai Cell Therapy Group Co.,Ltd","biomarkers":" PD-L1 • MSLN","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BZDS1901"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 11/30/2021","start_date":" 11/30/2021","primary_txt":" Primary completion: 07/30/2024","primary_completion_date":" 07/30/2024","study_txt":" Completion: 01/30/2025","study_completion_date":" 01/30/2025","last_update_posted":"2023-07-17"},{"id":"26dd7949-9dd6-4b50-b524-f82cd6d11b0b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05944185","created_at":"2023-07-13T18:10:50.357Z","updated_at":"2024-07-02T16:35:42.965Z","phase":"Phase 1/2","brief_title":"Phase I/II Study of αPD1-MSLN-CAR T Cells in MSLN-positive Advanced Solid Tumors","source_id_and_acronym":"NCT05944185","lead_sponsor":"Shanghai Cell Therapy Group Co.,Ltd","biomarkers":" PD-L1 • MSLN","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BZDS1901"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 09/01/2023","start_date":" 09/01/2023","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2023-07-14"},{"id":"8be2ee14-5e35-4a28-8a6d-71e0e53b1c4f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05373147","created_at":"2022-05-13T12:54:33.660Z","updated_at":"2024-07-02T16:36:01.813Z","phase":"Phase 1","brief_title":"αPD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors","source_id_and_acronym":"NCT05373147","lead_sponsor":"Shanghai Mengchao Cancer Hospital","biomarkers":" PD-L1 • PD-1 • IL6 • MSLN • IL2 • IL10","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • PD-1 • IL6 • MSLN • IL2 • IL10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BZDS1901"],"overall_status":"Recruiting","enrollment":" Enrollment 21","initiation":"Initiation: 10/30/2020","start_date":" 10/30/2020","primary_txt":" Primary completion: 02/01/2023","primary_completion_date":" 02/01/2023","study_txt":" Completion: 08/01/2023","study_completion_date":" 08/01/2023","last_update_posted":"2022-10-26"},{"id":"310da539-a784-44b1-83d7-d9346d60eb33","acronym":"","url":"https://clinicaltrials.gov/study/NCT04503980","created_at":"2021-01-18T21:35:54.015Z","updated_at":"2024-07-02T16:36:42.230Z","phase":"Phase 1","brief_title":"αPD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors","source_id_and_acronym":"NCT04503980","lead_sponsor":"Shanghai Cell Therapy Group Co.,Ltd","biomarkers":" PD-L1 • MSLN","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • BZDS1901"],"overall_status":"Recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 03/26/2020","start_date":" 03/26/2020","primary_txt":" Primary completion: 03/01/2021","primary_completion_date":" 03/01/2021","study_txt":" Completion: 06/01/2022","study_completion_date":" 06/01/2022","last_update_posted":"2020-08-07"},{"id":"1a05a158-2b35-483a-8c45-2aa44e439674","acronym":"","url":"https://clinicaltrials.gov/study/NCT04489862","created_at":"2021-01-18T21:34:24.718Z","updated_at":"2024-07-02T16:36:42.681Z","phase":"Phase 1","brief_title":"αPD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors","source_id_and_acronym":"NCT04489862","lead_sponsor":"Wuhan Union Hospital, China","biomarkers":" PD-L1 • MSLN","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • BZDS1901"],"overall_status":"Recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 05/13/2020","start_date":" 05/13/2020","primary_txt":" Primary completion: 06/01/2022","primary_completion_date":" 06/01/2022","study_txt":" Completion: 12/01/2022","study_completion_date":" 12/01/2022","last_update_posted":"2020-07-28"},{"id":"c2ebdc67-0d03-482c-9a55-4869e375c26d","acronym":"PAEMCMPAST","url":"https://clinicaltrials.gov/study/NCT03615313","created_at":"2021-01-17T17:13:11.016Z","updated_at":"2024-07-02T16:37:08.261Z","phase":"Phase 1/2","brief_title":"PD-1 Antibody Expressing mesoCAR-T Cells for Mesothelin Positive Advanced Solid Tumor","source_id_and_acronym":"NCT03615313 - PAEMCMPAST","lead_sponsor":"Shanghai Cell Therapy Research Institute","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN expression","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • BZDS1901"],"overall_status":"Unknown status","enrollment":" Enrollment 50","initiation":"Initiation: 08/06/2018","start_date":" 08/06/2018","primary_txt":" Primary completion: 08/03/2020","primary_completion_date":" 08/03/2020","study_txt":" Completion: 12/03/2020","study_completion_date":" 12/03/2020","last_update_posted":"2018-08-03"}]